Transdermal testosterone replacement therapy in men

M Iftekhar Ullah1
Daniel M Riche1,2
Christian A Koch1,3
1Department of Medicine, University of Mississippi Medical Center,
2Department of Pharmacy Practice, The University of Mississippi,
3GV (Sonny) Montgomery VA Medical Center, Jackson, MS, USA

Abstract: Androgen deficiency syndrome in men is a frequently diagnosed condition associated with clinical symptoms including fatigue, decreased libido, erectile dysfunction, and metabolic syndrome. Serum testosterone concentrations decline steadily with age. The prevalence of androgen deficiency syndrome in men varies depending on the age group, known and unknown comorbidities, and the respective study group. Reported prevalence rates may be underestimated, as not every man with symptoms of androgen deficiency seeks treatment. Additionally, men reporting symptoms of androgen deficiency may not be correctly diagnosed due to the vagueness of the symptom quality. The treatment of androgen deficiency syndrome or male hypogonadism may sometimes be difficult due to various reasons. There is no consensus as to when to start treating a respective man or with regards to the best treatment option for an individual patient. There is also lack of familiarity with treatment options among general practitioners. The formulations currently available on the market are generally expensive and dose adjustment protocols for each differ. All these factors add to the complexity of testosterone replacement therapy. In this article we will discuss the general indications of transdermal testosterone replacement therapy, available formulations, dosage, application sites, and recommended titration schedule.

Keywords: hypogonadism, transdermal, testosterone, sexual function, testosterone replacement therapy, estradiol

Introduction

Late onset hypogonadism with androgen deficiency syndrome in men is a frequently diagnosed condition associated with clinical symptoms including fatigue, decreased libido, erectile dysfunction, decreased muscle and lean body mass, low bone mineral density, metabolic syndrome, and depression.1–5 Total, free, and bioavailable testosterone and sex hormone binding globulin may all be significantly reduced in men with metabolic syndrome compared to those without metabolic syndrome.5

In older men an optimal plasma testosterone level is associated with reduced all-cause mortality,6 and serum testosterone concentrations decline steadily with age. Some studies report that the mean total serum testosterone concentration of men at age 75 years is about two thirds of the levels at age 25 years.7 Approximately 50% of men older than 80 years and about 20% of men older than 60 years have serum testosterone concentrations at least two standard deviations below the mean concentration for young men.8,9 The actual prevalence of androgen deficiency syndrome or male hypogonadism in men is not definitely known. When considering symptomatic androgen deficiency as defined by a total serum testosterone concentration below 300 ng/dL and/or free testosterone concentration below 5 ng/dL in addition to the presence of low sex drive, erectile
dysfunction, osteoporosis or fracture, or two or more of the following symptoms including sleep disturbance, depressed mood, lethargy, diminished physical performance, the prevalence of symptomatic androgen deficiency in men between age 30 and 79 years is about 6%.10

Obviously, the definition of male hypogonadism depends not only on clinical symptoms and signs but also on cutoff levels of serum testosterone concentrations. Most authorities would consider as the lower limit of the normal range a serum total testosterone concentration of 315 ng/dL in healthy nonobese men, and of 6.5 ng/dL for free testosterone (measured by equilibrium dialysis or absolutely reliable assays).7 A consensus statement by the International Society of Andrology, International Society for the Study of Aging Male, European Association of Urology, European Academy of Andrology, and American Society of Andrology, concluded that there are no generally accepted lower limits of normal serum testosterone and that men with a serum concentration above 350 ng/dL generally do not require substitution therapy, while men with serum testosterone concentrations below 230 ng/dL will usually benefit from testosterone replacement therapy (TRT).11

Of note, there are large inter-individual variations of free testosterone concentrations and it is unclear how a certain cutoff level of total or free serum testosterone can be used to confirm “normalez”. For instance, man A may have had a total testosterone value of 900 ng/dL at age 20 years and now at age 50 has a value of 400 ng/dL with symptoms of androgen deficiency syndrome, whereas man B with a total testosterone value of 400 ng/dL at age 50 years and no symptoms of androgen deficiency syndrome may have had a value of 500 ng/dL at age 20 years. The normal total serum testosterone range in healthy adult males is said to be between 315 and 1,000 ng/dL based on blood production and metabolic clearance rates.7

The prevalence of male hypogonadism may be underestimated, as not every man with symptoms of hypogonadism seeks treatment. Additionally, men reporting symptoms of hypogonadism may not be correctly diagnosed due to the vagueness of the symptoms. Even in patients with a confirmed diagnosis, the treatment course can be difficult due to lack of familiarity with treatment options.

Various therapy choices are available to replace testosterone in men including oral, intramuscular, subcutaneous, and transdermal preparations.12 Most men (age 22 to 69 years) prefer a topical gel product over an injection or patch due to its ease of use.13 Unfortunately, there is no consensus as to when to treat a patient, or what the best treatment option is for an individual patient. There are many factors that have to be considered in each individual with their unique genetic and environmental makeup which have not been well studied in large scale trials but rather become clear by practice-based evidence (see also The CARE [CAseREport] guidelines: consensus-based clinical case report guideline development).14,15

The topical formulations available on the market are generally expensive and dose adjustment protocols for each of them differ. All these factors add to the complexity of TRT for general practitioners.16 In this article, we will discuss the general indications of transdermal TRT, available formulations, dosage, application sites, and recommended titration schedule.

### Physiology of testosterone

Testosterone is essential for development and maintenance of various organs and physiological functions in men. It is a steroid hormone which exerts effects on the male throughout life.17,18 The male fetus develops the cells of Leydig around the seventh week of development which begin to produce testosterone. Testosterone leads to differentiation of the male fetal genitourinary tract with development of epididymis, seminal vesicles, and vas deferens. The external male genitalia begin to develop at around 8 weeks of fetal life. Testosterone starts to exert its effects on the development of secondary sexual characteristics in males during puberty. The hypothalamus begins to secrete gonadotropin-releasing hormone (GnRH) from the hypothalamus in a pulsatile fashion, with release of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary (Figure 1).

LH stimulates the Leydig cells in the testes to produce testosterone, causing development of male secondary sexual characteristics. An elevated serum testosterone concentration causes negative feedback inhibition of the hypothalamic-pituitary-gonadal (HPG) axis by decreasing GnRH and LH/FSH from the hypothalamus and anterior pituitary. In addition to development of secondary sexual characteristics in males, testosterone also has various physiological effects in the body including maintaining lean muscle and bone mass, spermatogenesis, libido, improving insulin sensitivity, and glucose metabolism, etc.

After secretion by the testes, about 97% of testosterone becomes either loosely bound with plasma albumin or more tightly bound with a beta globulin called sex hormone-binding globulin (SHBG). The rest circulates in the blood in free/unbound form.18 The circulating testosterone is either transferred to the tissues or degraded into inactive products that are subsequently excreted. Factors that increase SHBG,
Transdermal testosterone replacement therapy

like hyperthyroidism, cirrhosis of the liver, aging, and others decrease the amount of bioavailable testosterone in the circulation. Much of the testosterone that becomes fixed to the tissues is converted within the tissue cells to dihydrotestosterone by the enzyme 5α-reductase, especially in certain target organs such as the prostate gland in the adult and the external genitalia of the male fetus. Some actions of testosterone are dependent on this conversion, whereas other actions are not. Testosterone that does not become fixed to the tissues is rapidly converted, mainly by the liver, into androsterone and dehydroepiandrosterone and simultaneously conjugated as either glucuronides or sulfates. These are excreted from the body through bile or urine.

Of note, estrogen-mediated actions of testosterone in men include feedback regulation of LH, skeletal homeostasis, lipid metabolism, and others. Estrogenic actions in men can occur through blood borne estrogens and through local aromatization of testosterone.

Approximately 0.3% of testosterone is converted into estradiol by aromatase (CYP19A1), an enzyme expressed in the brain, liver, and adipose tissues. In obese men, the increased amount of fat leads to increased extragonadal aromatase activity, resulting in increased concentrations of estradiol. High circulating concentrations of estradiol down regulate the HPG axis and decrease the amount of circulating testosterone. Up to 80% of plasma estradiol originates from aromatization of testosterone and less than 20% of estradiol in the circulation is secreted by the testes. Serum estradiol concentrations in men are around 20 to 30 pg/mL and do not vary significantly with age with some elderly men having higher estradiol serum concentrations than postmenopausal women. In aging men, both estrogen and testosterone are important in maintaining bone formation. Estrogens also play a role in energy balance and glucose homeostasis.

**Diagnosis of male hypogonadism**

The symptoms of male hypogonadism may be nonspecific and often mimic many other diseases, making the diagnosis difficult. As a general rule, any chronic (inflammatory) condition that puts one out of eustasis may lead to “sick gonadotroph syndrome” (Figure 2). In this context, chronic pain and/or chronic opioid use can cause hypogonadism which can be successfully treated by testosterone gel. Patients can generally present with unexplained fatigue, depression, loss of libido, or erectile dysfunction (Table 1). After exclusion of other diseases, hypogonadism should be suspected and appropriate tests should be ordered to establish the diagnosis (Figure 2 based on Wang et al regarding serum testosterone cutoff concentrations).

The challenge arises when a reference range for normal serum testosterone is sought for the elderly male population since an individual’s testosterone concentration constantly declines naturally over the later decades of life. A recent study proposed that the 2.5th percentile (184 ng/dL of serum total testosterone) in a reference group of healthy elderly men may provide age appropriate thresholds for defining the cutoff point for low testosterone. Of note, more than 80% of circulating estradiol in men comes from the conversion/aromatization of testosterone. Estrogen deficiency may primarily account for increases in body fat. Apparently, men with a testosterone level below 200 ng/dL start to experience loss of lean mass and muscle strength, acknowledging, however, that sensitivity of various androgen target tissues varies, ie, this level of 200 ng/dL is not an absolute number.

After diagnosing hypogonadism, the currently available treatment options should be considered and discussed with the patient. The oral formulations containing 17-α-testosterone are no longer used due to their potential liver toxicity because of the hepatic first pass metabolism, while there is no published evidence that indicates nonoral formulations causing liver toxicity. Buccal formulations have the convenience of oral administration with low potential for hepatotoxicity as they bypass the hepatic first pass metabolism, but have a

---

**Figure 1** Hypothalamic-pituitary-gonadal axis and testosterone secretion. **Abbreviations:** FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone.
Exclude other illness that may cause similar symptoms: depression, hypothyroidism, sleep apnea, anemia, untreated diabetes, inflammatory arthritis, COPD, renal failure, HIV, chronic pain and opiate use (drug-induced).

Symptoms of hypogonadism

Treat other illness if present, then re-evaluate

Symptoms persists

Check morning serum total testosterone on two occasions

>350 ng/dL

No replacement necessary in most cases

<230 ng/dL

Testosterone replacement in most cases

<150 ng/dL

Look for pituitary etiology (prolactin)

230–350 ng/dL

Repeat total testosterone with free (bioavailable) testosterone, LH, estradiol

Low (<65 pg/dL) free testosterone

Estradiol <10 pg/dL

Symptoms persists

Re-assess after 3 months of therapy

If no improvement in libido, muscle function, or body fat, stop treatment and assess for other causes of symptoms

Figure 2 Algorithm for diagnosis and treatment of male hypogonadism.

Notes: If significant symptoms exist, may consider treatment regardless of additional laboratory results. Adapted with permission from Thieme. Ullah MI, Washington T, Kazi M, Tamanna S, Koch CA. Testosterone deficiency as a risk factor for cardiovascular disease. Horm Metab Res. 2011;43(3):153–164. Copyright © 2011.

Abbreviations: COPD, chronic obstructive pulmonary disorder; HIV, human immunodeficiency virus; LH, luteinizing hormone.

Table 1 Symptoms and signs of testosterone deficiency

| Typical symptoms and signs          | Nonspecific symptoms and signs                     |
|------------------------------------|---------------------------------------------------|
| Reduced libido, erectile dysfunction| Generalized fatigue                                |
| Decreased spontaneous (morning) erections | Reduced muscle bulk and strength                  |
| Loss of body (axillary and pubic) hair | Poor concentration and memory                      |
| Small (especially <5 mL) or shrinking testes | Sleep disturbance, increased sleepiness            |
| Infertility, low sperm count        | Mild anemia (iron deficiency)                      |
| Pathological fracture, low bone mineral density | Increased body fat and metabolic syndrome |

Notes: Data from Ullah et al, and Koch and Zitzmann.41,42,58

short duration of action requiring 2–3 times daily dosing, mouth-related adverse effects (gum and mouth pain, gum edema, bitter taste, taste perversion),16 and the clinical response is less consistent. Intramuscular depot injection of testosterone cypionate is less expensive and can be administered every 1–4 weeks. A major disadvantage is the strongly fluctuating concentrations of plasma testosterone which are at least 50% of the time not in the physiological range.37 This also causes supraphysiologic serum testosterone concentrations within 2 to 3 days of injection and a slow decline to subnormal levels within 1 to 2 weeks. This non-circadian type of roller coaster pharmacokinetic response may cause rapid swings in energy, mood, and sexual function.38 Application regimens of 200 mg every 2 weeks and 300 mg every 3 weeks seem to be effective in moving serum LH concentrations into the normal range.39 Implantable testosterone pellets are also available but require surgical intervention, may be painful, and are sometimes extruded spontaneously from the implant site. Convenience appears to be the most important factor in patients’ decision to choose subcutaneous pellets therapy, but the cost of therapy is the primary reason for discontinuing it.40 Besides intramuscular testosterone injection, transdermal TRT (gel and patch) are the most common formulations used in the US to treat hypogonadism. We will discuss the dosage and application procedures of the commonly available transdermal...
testosterone formulations in the US. We have also compiled a table (Table 2) which summarizes some important journal articles on recent advances in TRT.

### Transdermal drug delivery system

This is a method of drug administration which allows application of a discrete dose of the drug by applying it on the intact skin, which is absorbed at a controlled rate into the systemic circulation. The skin serves as a reservoir for the sustained release of testosterone into the systemic circulation. It is used for many medications and has the advantage of high bioavailability, absence of hepatic first pass metabolism, increased therapeutic efficacy, and steadiness of plasma concentrations of the drug. For testosterone replacement, two subtypes of transdermal application systems are available in the US. One is in the form of a patch containing testosterone that is applied to the skin daily. Androderm (Actavis, Inc., Dublin, Ireland) is the only testosterone patch available in the US. Testoderm (Actavis, Inc.) is another testosterone patch (applied on scrotal skin) which is not available in the US. The others are in the form of gels containing testosterone which is applied directly on the skin. Several gel formulations are available in the US and doses and application sites for each medication vary, increasing the difficulty in prescribing and monitoring the treatment response for the provider. In the next few sections, we will try to summarize the similarities and differences of each medication. Of note, a study from 1989 utilizing testosterone transdermally containing 5, 10, or 15 mg of testosterone showed that peak concentrations of testosterone were achieved 3 to 8 hours after scrotal application in hypogonadal men. In that study, a potential disadvantage expresses 5-alpha reductase.
Transdermal patch

Androderm® is a transdermal testosterone patch available in the US and some other countries but not in the UK. It is supplied in 2 mg/day and 4 mg/day dose forms. The other testosterone patch called Testoderm is no longer available on the market. It is recommended to start with the application of one 4 mg/day uncut/torn Androderm patch nightly on the clean, dry, and unbroken skin on the back, abdomen, upper arms, or thighs only. It should not be applied to skin on the scrotum, buttocks, or any bony area. The sites of application should be rotated weekly and should not be used more frequently than every 7 days. This may reduce the risk for skin irritation. More than one patch applied simultaneously may be required to reach adequate serum testosterone concentrations.

The patient should avoid showering, swimming, or washing the site for at least 3 hours after application to allow adequate absorption of the drug into the subcutaneous tissue where it remains stored for continuous release into the systemic circulation. Minor skin irritation (occurs in up to 30% of men) may be treated by applying over the counter hydrocortisone cream on the affected skin after removal of the patch. If a patch is dislodged from the skin prior to noon, a new patch can replace it; if the patch is dislodged later in the day, the patient should wait until the next scheduled application. For dose titration, an early morning total serum testosterone should be checked at least 2 weeks after initiation of therapy, following system application the previous evening. The target range of serum testosterone is between 400 and 930 ng/dL.

Transdermal gels

Several testosterone gel formulations are available for topical use in the US. These include Androgel® (1% and 1.62%) (AbbVie Inc., Lake Bluff, IL, USA), Axiron® (Eli Lilly and Company, Indianapolis, IN, USA), Fortesta® (Endo Pharmaceuticals Inc., Malvern, PA, USA), and Testim® (Auxilium Pharmaceuticals Inc., Chesterbrook, PA, USA). Their indications, adverse effects, and contraindications are fairly similar, but the dose adjustments and application sites differ significantly and are not interchangeable (Table 3).

In general, the patients should wash hands immediately with soap and water after applying the gel and cover the application site with clothing after the gel has dried. They should also wash the application site thoroughly with soap and water, if skin to skin contact of the application site with another person is anticipated. The dose should be titrated based on the (total) serum testosterone concentration checked at least 2–4 weeks after therapy initiation or after any dose adjustment. In a study with healthy young men, 150 mg of topical testosterone gel administration resulted in maximum total serum testosterone concentrations 3 hours after administration without suppressing LH. Serum testosterone concentrations can generally be assessed any time after the individual man has been on treatment for at least 1 week.

Kinetics data of different transdermal testosterone formulations are presented in Table 4. Interestingly, a recent study of healthy young men who received 150 mg of testosterone in topical gel showed a maximum total serum testosterone concentration 3 hours after administration without suppression of LH at any time point over 1 hour intervals for 7 hours after gel administration. Administration of 2 mg estradiol in topical gel led to maximum estradiol serum concentration 2 hours after administration and did not suppress absolute LH concentrations.

Androgel®: This medication comes in two different formulations, 1% and 1.62%. Both are applied to the clean and dry intact skin of the shoulder or upper arm once daily in the morning. The dosage and administration of each differs from the others. Each comes in a pump and in a packet. The starting dose of Androgel 1% is 50 mg of testosterone (four pump actuation, two 25 mg packets or one 50 mg packet). On the other hand, Androgel 1.62% should be started at 40.5 mg (two pump actuation, 20.25 mg each or one 40.5 mg packet). The dose should be titrated based on the predose morning serum concentration of (total) testosterone checked at least 2–4 weeks of therapy initiation or after any dose adjustment. The 1.62% formulation is more concentrated which allows...
Table 4 Kinetics and composition of different transdermal testosterone formulations<sup>a</sup>–<sup>c</sup>

| Medication | Absorption       | Duration                        | Inactive ingredients                                                                 |
|------------|------------------|---------------------------------|--------------------------------------------------------------------------------------|
| Androgel 1%| Continuous –     | 5 days after achieving steady   | Carbomer 980, ethyl alcohol 67.0%, isopropyl myristate, sodium hydroxide, purified water |
|            | 10% bioavailable | state                            |                                                                                      |
| Androgel 1.62%| Continuous     | 48–72 hours                      | Carbomer 980, ethyl alcohol, isopropyl myristate, sodium hydroxide, purified water    |
| Axiron     | Reservoir of testosterone and octisalate | 7–10 days after reaching steady state | Ethanol, isopropyl alcohol, octisalate, and povidone                                  |
| Fortesta   | Continuous       | 24–48 hours<sup>d</sup>          | Propylene glycol, purified water, ethanol, 2-propanol, oleic acid, carbormer 1382, triethanolamine, and butylated hydroxytoluene |
| Testim 1%  | Sustained release – | 24–48 hours<sup>d</sup>        | Pentadecalactone, carbopol, acrylates, propylene glycol, glycerin, polyethylene glycol, ethanol (74%), tromethamine, purified water |
|            | 10% bioavailable |                                  |                                                                                      |

Notes: <sup>a</sup>Metabolism of any testosterone is hepatic via (1) aromatase and (2) 5-alpha reductase. Major active metabolites of testosterone are estradiol and dihydrotestosterone; <sup>b</sup>elimination t<sub>1/2</sub> of any testosterone preparation ~10–100 minutes; <sup>c</sup>distribution: all preparations are bound: 98% (40% sex hormone-binding globulin) and free: 2%; <sup>d</sup>based on time to baseline in mean total testosterone concentrations reported in product information.

less gel to be applied and improves skin permeation compared to the 1% gel.

Axiron 2%<sup>e</sup>: This is the only formulation that has received US Food and Drug Administration (FDA) approval for application under arms (axilla). It is an odorless formulation that comes in a metered dose pump with a silicone applicator. The starting dose is one pump actuation (30 mg) to be applied in each axilla (total 60 mg/day) every morning. The dose should be titrated based on the serum concentration of testosterone after 2–8 hours of application, checked after at least 2 weeks of therapy initiation or after any dose adjustment. It has minimal local adverse reactions including skin erythema and edema. Its efficacy is not compromised by concomitant use of deodorant or antiperspirant but it is recommended to apply deodorant prior to application of Axiron to avoid contamination of deodorant sticks.<sup>59</sup>

Fortesta 2%<sup>f</sup>: This is a clear, odorless gel which is low in volume and is one of the least expensive transdermal formulations available.<sup>60</sup> This formulation comes in only pump dispensing format. It is started at 40 mg of testosterone daily (four pump actuation) applied every morning on the dry, intact skin of the front or inner thighs. The dose should be titrated based on the serum concentration of testosterone after a single blood draw after 2 hours of application, checked after at least 2 weeks of therapy initiation or after any dose adjustment. This formulation has been reported to restore testosterone concentrations in 77% of men in a study, without risk of supra-physiologic testosterone concentrations.<sup>61</sup>

Testim 1%<sup>g</sup>: This is a translucent gel formulation with slightly musky odor that has variable patient acceptability. The formulation contains an emollient which helps reduce drying out of the skin and enables higher testosterone absorption.<sup>62,63</sup> The drug is provided in 5 g tubes, each containing 50 mg of testosterone. The recommended starting dose is 5 g of gel (one tube) containing 50 mg of testosterone to be applied once daily in the morning to clean, dry intact skin of the shoulders or upper arms. Morning serum testosterone concentrations should be measured approximately 2 weeks after initiation of therapy to ensure that proper serum testosterone concentrations are achieved. Reportedly, Testim 1% produces higher serum concentrations and greater bio-availability than Androgel 1% with C<sub>max</sub> estimates for total testosterone, dihydrotestosterone, and free testosterone being greater (30%, 19%, and 38%, respectively) following the application of Testim compared to AndroGel.<sup>53</sup>

Potential adverse effects of testosterone replacement
- Worsening symptoms of benign prostatic hyperplasia (likely preventable or being averted with co-administration of finasteride)<sup>64</sup>
- Virilization in females or children with accidental exposure
- Polycythemia<sup>65,66</sup>
- Edema
- Gynecomastia
- Dyslipidemia
- Hypercalcemia
- Application site reaction
- Increased risk of prostate cancer<sup>66,67</sup> (unproven)
- Emotional lability (putative)
- Hypertension (putative)
- Alopecia
- Priapism<sup>68,69</sup> (unlikely).

Contraindications to testosterone therapy
- History of breast or prostate cancer<sup>41,58</sup>
- Presence of palpable prostate nodule or induration<sup>41,58</sup>
- Prostate-specific antigen (PSA) >4 ng/mL or >3 ng/mL in men at high risk for prostate cancer such as African-Americans, or men with first degree relatives with prostate cancer, without further urological evaluation\textsuperscript{41,58}
- Untreated severe obstructive sleep apnea\textsuperscript{41,58}
- Uncontrolled or poorly controlled heart failure\textsuperscript{41,58}
- Severe lower urinary tract symptoms with International Prostate Symptom Score above 19 (symptoms unchanged or even improved)\textsuperscript{70,71}
- Hematocrit >50\%\textsuperscript{,41,58}

Disadvantages of transdermal TRT
The transdermal formulations available for TRT are generally expensive. Some patients may develop mild skin irritation while others may develop more serious skin reactions. Those who sweat excessively may have difficulty wearing the patch. Transference is a major concern and has been the topic of FDA warnings.\textsuperscript{72} Accidental transference can lead to virilization of contacts, especially in children.\textsuperscript{73} To prevent it, areas of application should be covered with clothing as soon as the gel has dried. Hands should be thoroughly washed with soap and water after application. If skin to skin contact is anticipated, the area should be washed thoroughly before contact. Swimming and bathing should be avoided for at least 2 hours after application. Special care must also be taken to avoid any contact possibility with pregnant women, as there is potential for teratogenicity.

Monitoring of TRT
Patients treated with testosterone replacement should be monitored for both treatment response as well adverse effects. They should be clinically evaluated and their serum testosterone concentrations should be checked 2–3 months after initiation of therapy and after adjusting the dose. The target serum testosterone concentration to be achieved for injectable testosterone enanthate or cypionate is said to be around 400–700 ng/dL which has been considered to be eugonadal by the Endocrine Society clinical practice guideline (2010).\textsuperscript{58,74} For other testosterone formulations, no specific range is given other than “mid-normal,” presumably also 400–700 ng/dL. Obviously, as stated before, there are large inter-individual variations and the serum testosterone concentration should therefore be seen in the context of signs and symptoms of each individual man. Higher (up to 1,000 ng/dL) and lower (as low as 300 ng/dL) concentrations may be considered acceptable responses to treatment. Some panelists of the Endocrine Society clinical practice guideline favored treating symptomatic older men who had serum testosterone concentrations below the lower limit of normal healthy young men (300 ng/dL\textsuperscript{,}2\textsuperscript{1}) while others were in favor of not treating unless the testosterone concentration is below 200 ng/dL.\textsuperscript{59} The timing of serum concentration measurement varies slightly depending on the preparation used, which has been summarized in Tables 3 and 4. Whereas the recommendation for injectable testosterone esters is to check the serum concentration midway between injections, it is recommended for serum testosterone to be evaluated 3 to 12 hours after application of the transdermal patch, to assess serum testosterone immediately before or after application of fresh system of buccal testosterone, to measure serum testosterone any time after the patient has been on treatment with gel for at least 1 week, and to evaluate serum testosterone at the end of the dosing interval for testosterone pellets, all with the aim to achieve “mid-normal” range of serum testosterone concentrations.

Monitoring for adverse effects from TRT should also be done. A PSA concentration, digital rectal examination, and hematocrit should be performed at baseline and at 3 months, 6 months, then yearly after TRT is initiated. If the hematocrit rises above 54\%, treatment should be discontinued until resolution to a safe level.\textsuperscript{58} We feel such a hematocrit level should be 45\% and then testosterone therapy can be reinitiated at reduced dose compared to the prior dose.\textsuperscript{58} Consider discontinuation of TRT and/or referral to a urologist if PSA measurements increase in consecutive 6-month intervals, or an increase of serum PSA >1.4 ng/mL in a year.\textsuperscript{58} If the digital rectal examination is abnormal, a biopsy should be performed to rule out prostate cancer. Additionally, a voiding assessment and breast examination should be performed at baseline and annually as long as TRT is continued. In men with osteoporosis or a history of low trauma fracture, bone mineral density of the lumbar spine should be measured after 1 to 2 years of continued TRT.

Timeline of response to therapy after testosterone replacement
The clinical response to transdermal testosterone supplement is variable. Generally, it takes 4–12 weeks to restore the serum testosterone concentration to physiological range, depending on the initial concentration of the hormone as well as the type of formulation used. Serum testosterone is usually measured to monitor response to therapy and achievement of a eugonadal state (generally considered to be reflected by a serum testosterone concentration between 400 and 700 ng).\textsuperscript{58} However, a recent study has suggested
that it may sometimes be inaccurate because of abnormal fluctuation of other circulating androgens. Improvement in sexual desire and function as well as mood and energy occurs early in the course of treatment, approximately within 3–6 weeks. 

One can begin to see improved muscle mass and strength, reduced adiposity, and an increasing hematocrit within 3 months which reaches its maximum at around 12 months. The lipid profile begins to improve in 3–4 months, with maximum effect attained in 12 months for total cholesterol and 22 months for triglyceride, high density lipoprotein, and low density lipoprotein. A decline in fasting blood glucose and HbA1c may be observed after 3 months with further decrease after 12 months.

Effects of testosterone on bone mineral density take longer to appear. It may take 6 months to see the initial effect and may take 36 months or longer to reach the maximum benefit. Patients with metabolic syndrome experience maximum benefit in waist circumference, fasting blood glucose, and blood pressure within 12 months. It is important to monitor blood glucose concentrations in diabetic patients and titrate down anti-diabetic medications if necessary, as TRT improves glycemic control and may precipitate hypoglycemia.

As per the Endocrine Society clinical practice guideline, men should be monitored for a clinical response and any adverse effects as well as for serum testosterone concentrations, hematocrit, and PSA every 3 months. Testosterone therapy can inhibit hepcidin transcription and is associated with increased iron incorporation into red blood cells and increased erythropoietin concentrations. If the hematocrit rises above 54%, it has been recommended to hold TRT until the hematocrit decreases to a “safe” level (for instance, to less than 45% to lower the risk of cardiovascular death and major thrombosis). If the hematocrit rises above 45%, whole blood viscosity increases above normal. Therefore, we would wait until the hematocrit drops to 45% and then reinstitute testosterone therapy at reduced dose.

A recent study of medical claims analysis has revealed that adherence to the topical TRT among hypogonadal patients is fairly low. Only 34% of patients continued with treatment after 6 months of therapy and only 15% continued after 1 year. Adherence to both Testim and Androgel were similar in this study. It is not clear what contributes to this low adherence to TRT. Several factors may be accountable. Cost of medication always is a major factor in adherence to any therapy. Those who have no prescription coverage or who have high copay may be less likely to continue topical testosterone. Some patients may also have unrealistic expectations from the therapy. As it may take up to 3 months to demonstrate a clinical response, some men may be reluctant to continue over a longer duration. The physicians must discuss the goals of therapy and encourage patients to not discontinue TRT without consulting the prescribing provider. If a patient does not achieve minimal biochemical goals (ie, serum testosterone >400 ng/dL) with a certain formulation after 3 months, or does not experience symptomatic improvement despite biochemical replacement, it is reasonable to switch to a different transdermal formulation. A study by Grober et al found that hypogonadal symptoms improved in a significant proportion of men who underwent a brand substitution (from Androgel to Testim and vice versa) after an initial suboptimal biochemical or symptomatic response with either product. If transdermal treatment does not achieve the goal, or cost becomes an obstacle, use of intramuscular testosterone enanthate or cypionate may always remain as a reasonable alternative therapy.

Conclusion

Transdermal TRT can replace testosterone in men with hypogonadism and restore a steady testosterone concentration in the blood. Transdermal TRT has a more favorable adverse effect profile when compared to buccal testosterone formulations. It also has better patient acceptance when compared to injectable testosterone forms. Different formulations available in the US have different recommended dosages and application sites. Familiarity with each testosterone formulation is needed for the prescribing providers to appropriately administer and monitor efficacy of transdermal TRT. The patients should also be instructed properly to exercise caution to minimize adverse effects and accidental transferral.

Disclosure

The authors report no conflicts of interest in this work.

Resources

1. Bhasin S, Cuningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. Available from: https://www.endocrine.org/-/media/endosociety/Files/Publications/Clinical%20Practice%20Guidelines/FINAL-Androgens-in-Men-Standalone.pdf. Accessed November 10, 2013.

2. Virtual Library. International Society of Andrology. Available from: http://www.andrology.org/library. Accessed December 5, 2013.
References

1. Rao PM, Kelly DM, Jones TH. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. *Nat Rev Endocrinol*. 2013;9(8):479–493.

2. Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. *J Endocrinol*. 2013;217(3):R47–R71.

3. Giannouli MG, Martin JC, Nair KS, Unpleby AM, Sonksen P. Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? *Endocr Rev*. 2012;33(3):314–377.

4. Shi Z, Araujo AB, Chubb SA, et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. *J Clin Endocrinol Metab*. 2013 Nov 20. [Epub ahead of print].

5. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. *Endocr Rev*. 2005;26(6):833–876.

6. Marfan SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. *J Clin Endocrinol Metab*. 2001;86(2):724–731.

7. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. *J Clin Endocrinol Metab*. 2002;87(2):589–598.

8. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. *J Clin Endocrinol Metab*. 2007;92(11):4241–4247.

9. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. *Nat Rev Endocrinol*. 2011;43(3):153–164.

10. Smith RP, Khanna A, Coward RM, et al. Factors influencing patient decisions to initiate and discontinue subcutaneous testosterone pellets (testopel) for treatment of hypogonadism. *J Urol*. 2011;185(2):548–554.

11. Koch CA, Zitzmann M. Testosterone deficiency or male hypogonadism. *Contemporary Endocrinology: Endocrine Hypertension*. New York: Springer; 2013.

12. Smith RP, Khanna A, Coward RM, et al. Factors influencing patient decisions to initiate and discontinue subcutaneous testosterone pellets (testopel) for treatment of hypogonadism. *J Sex Med*. 2013;10(9):2326–2333.

13. Ullah MI, Washington T, Kazi M, Tamanna S, Koch CA. Testosterone deficiency as a risk factor for cardiovascular disease. *Horm Metab Res*. 2011;43(3):153–164.

14. Koch CA, Zitzmann M. Testosterone deficiency or male hypogonadism. *In: Koch CA, Chrousos GP*, editors. *Contemporary Endocrinology: Endocrine Hypertension*. New York: Springer; 2013.

15. Basaria S, Dobs AS. New modalities of transdermal testosterone replacement therapy and monitoring of late-onset hypogonadism in males. *Aging Male*. 2007;217(3):R47–R71.

16. Laron PR, Kronenberg HM, Melmed S, Polonsky KS, editors. *Endocrinology*. 12th ed. New York: Elsevier; 2013.

17. Rocha-Schaeffer C, Koch CA, Swerdloff RS, et al. Testosterone deficiency as a risk factor for cardiovascular disease. *Horm Metab Res*. 2011;43(3):153–164.

18. Koch CA, Zitzmann M. Testosterone deficiency or male hypogonadism. *In: Koch CA, Chrousos GP*, editors. *Contemporary Endocrinology: Endocrine Hypertension*. New York: Springer; 2013.

19. Felder M, Fass F, Kooistra HS, et al. Testosterone replacement therapy: an overview. *Urol Nurs*. 2006;26(4):253–259, 269; quiz 260.

20. Hall JE. Reproductive and Hormonal Functions of the Male. In: *Gynaton and Hall Textbook of Medical Physiology*. 12th ed. New York: Elsevier; 2010.

21. Phillips KL, Phillips KA, Sowers JR, et al. Testosterone and cardiovascular disease. *Circulation*. 2009;119(7):819–829.

22. Dandona P, Rosenberg MT. A practical guide to male hypogonadism in clinical practice and guideline development. *J Urol*. 2004;172(2):682–696.

23. Griffin JE, Wilson JD. Disorders of the testis and male reproductive tract. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. *Williams Textbook of Endocrinology*. 10th ed. New York: WB Saunders; 2003:709–770.

24. Ohl DA, Quillach C, Sideras K, Boloña ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. *J Clin Endocrinol Metab*. 2009;94(11):2101–2106.

25. Ohl DA, Quillach C, Sideras K, Boloña ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. *J Clin Endocrinol Metab*. 2009;94(11):2101–2106.

26. Felder M, Fass F, Kooistra HS, et al. Testosterone replacement therapy: an overview. *Urol Nurs*. 2006;26(4):253–259, 269; quiz 260.
44. Gooren LJ, Bunck MC. Androgen replacement therapy: present and future. Drugs. 2004;64(17):1861–1891.
45. Swerdloff RS, Wang C. Androgens and the ageing male. Best Pract Res Clin Endocrinol Metab. 2004;18(3):349–362.
46. Bouloix P. Testim 1% testosterone gel for the treatment of male hypogonadism. Clin Ther. 2005;27(3):286–298.
47. Hong BS, Ahn TY. Recent trends in the treatment of testosterone deficiency syndrome. Int J Urol. 2007;14(11):981–985.
48. Jones TH. Testosterone replacement therapy, Br J Hosp Med (Lond). 2007;68(10):547–553.
49. Srinivas-Shankar U, Sharma D. Testosterone treatment in elderly men. Adv Ther. 2009;26(1):25–39.
50. Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. J Sex Med. 2011;8(3):639–654; quiz 655.
51. Giagulli VA, Triggiani V, Corona G, et al. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations. Cure Pharm Des. 2011;17(15):1500–1511.
52. Abadilla KA, Dobs AS. Topical testosterone supplementation for the treatment of male hypogonadism. Drugs. 2012;72(12):1591–1603.
53. Dinsmore WW, Wylie MG. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men. BJU Int. 2012;110(2):162–169.
54. Jenerowicz D, Polanska A, Olek-Hrab K, Silny W. Skin hypersensitivity reactions to transdermal therapeutic systems – still an important clinical problem. Ginekol Pol. 2012;83(1):46–50.
55. Foco A, Hadziabdic J, Becic F. Transdermal drug delivery systems. Med Arch. 2004;58(4):230–234.
56. Cunningham GR, Cordero E, Thornby JI. Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA. 1989;261(17):2525–2530.
57. Eisenegger C, Von Eckardstein A, Fehr E, Von Eckardstein S. Pharmacokinetics of testosterone and estradiol gel preparations in healthy young men. Psychoneuroendocrinology. 2013;38:171–178.
58. Bhasin S, Cunningham GR, Hayes FJ, et al. Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–2559.
59. Wang C, Imani N, Arver S, McLachlan RI, Souliis T, Watkinson A. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Clin Endocrinol. 2011;75(6):836–843.
60. Abadilla KA, Dobs AS. Topical testosterone supplementation for the treatment of male hypogonadism. Drugs. 2012;72(12):1591–1603.
61. Abadilla KA, Dobs AS. Testosterone treatment of men with androgen deficiency syndromes. Expert Opin Pharmacother. 2012;13(4):507–516.
62. McNicholas T, Ong T. Review of Testim gel. Expert Opin Pharmacother. 2006;7(4):477–484.
63. Marbury T, Hamill E, Bachand R, Sebere T, Smith T. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel. Biopharm Drug Dispos. 2003;24(3):115–120.
64. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89(2):503–510.
65. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451–1457.
66. Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560–2575.
67. Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res. 2009;21(1):9–23.
68. Burnett AL, Kan-Dobrosky N, Miller MG. Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. J Sex Med. 2013;10(4):1151–1161.
69. Morrison BF, Reid M, Madden W, Burnett AL. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report. Androlgy. 2013;1(4):576–582.
70. Francomano D, Ilaqua A, Bruzziches R, Lenzi A, Aversa A. Effects of 5-year treatment with testosterone undeconoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology. Epub October 15, 2013.
71. Yassin D-J, El Douaihy Y, Yassin AA, Kashanian J, Shabsigh R, Hammerer PG. Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study. World J Urol. Epub October 18, 2013.
72. Accessdata FDA. Available at: http://www.accessdata.fda.gov/drug-satff_docs/label/2002/214544btl.pdf. Accessed November 10, 2013.
73. Kunz GJ. Virilization of young children after topical androgen use by their parents. Pediatr. 2004;114(1):282–284.
74. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91(6):1995–2010.
75. Di Luigi L, Sgrò P, Aversa A, et al. Concerns about serum androgens monitoring during testosterone replacement treatments in hypogonadal male athletes: a pilot study. J Sex Med. 2012;9(3):873–886.
76. Wang C, Swerdloff RS, Iranmanesh A, et al; Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2839–2853.
77. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675–685.
78. Miner MM, Bhattacharya RK, Blick G, Kusner H, Khera M. 12-Month observation of testosterone replacement effectiveness in a general population of men. Postgrad Med. 2013;125(2):8–18.
79. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30(6):726–733.
80. Hijazi RA, Cunningham GR. Andropause: is androgen replacement therapy indicated for the aging male? Annu Rev Med. 2005;56:117–137.
81. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Chaner KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89(7):3313–3318.
82. Ginzburg E, Klimas N, Parvus C, et al. Long-term safety of testosterone and growth hormone supplementation: a retrospective study of metabolic, cardiovascular, and oncologic outcomes. J Clin Med Res. 2010;2(4):159–166.
83. Emmelot-Vonk MH, Verhaar HJJ, Nakahi Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299:39–52.
84. Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol. 2001;54(6):739–750.
85. Bhattacharya RK, Khera M, Blick G, Kusner H, Nguyen D, Miner MM. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS). BMC Endoc Disord. 2011;11(1):18.
86. Guo W, Bachman E, Li M, et al. Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell. 2013;12(2):280–291.
87. Marchioli R, Finazzi G, Specchia G, et al; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33.

88. Spivak JL. Polycythemia vera, the hematocrit, and blood-volume physiology. N Engl J Med. 2013;368(1):76–78.

89. Wells RE, Merrill EW. Influence of flow properties of blood upon viscosity-hematocrit relationships. J Clin Invest. 1962;41:1591–1598.

90. Schoenfeld MJ, Shortridge E, Cui Z, Muram D. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis. J Sex Med. 2013;10(5):1401–1409.

91. Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res. 2008;20(2):213–217.